Treating paediatric glaucoma

Article

Penetrating deep sclerectomy (combining deep sclerectomy with trabeculectomy) delivers promising intermediate results in the treatment of paediatric glaucoma, according to the conclusions of a study published in the January issue of Ophthalmology.

Penetrating deep sclerectomy (combining deep sclerectomy with trabeculectomy) delivers promising intermediate results in the treatment of paediatric glaucoma, according to the conclusions of a study published in the January issue of Ophthalmology.

Sylvain Roy, MD, PhD of the Jules Gonin Eye Hospital at the University of Lausanne, Switzerland and colleagues conducted a retrospective non-interventional case series study of paediatric (mean preoperative age, 3.6±4.5 years) glaucoma patients (n=28; eyes, n=35) undergoing combined deep sclerectomy and trabeculectomy surgery between March 1997 and October 2006. Patients - who were examined preoperatively, and then postoperatively at day 1, day 7 and at 1, 2, 3, 4, 6, 9 and 12 months, and every six months thereafter - were assessed for intraocular pressure (IOP) change, a change in the number of medications prescribed, complications, and surgical revisions, among other factors. The mean follow-up was 3.5±2.9 years.

Preoperatively, mean IOP was 31.9±11.5 mmHg, which had decreased by 58.3% at the end of follow-up. Sight-threatening complications were more common for patients with refractory glaucomas; the number of these complications was also associated with the severity of the condition and the number of previous surgeries. At nine years postoperatively, the complete success rate was 52.3%; the qualified success rate at this point was 70.6%.

The team concluded that these intermediate results of combined deep sclerectomy and trabeculectomy are promising, and noted that these results are more favourable than earlier treatments trialled for this indication.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.